New Study Finds GLP-1 Medications Decrease Risk of Major Cardiovascular Events and Amputations for Patients with Moderate Peripheral Artery Disease
A large retrospective review of over 100,000 patients found the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in moderate peripheral artery disease (PAD) is associated with a decreased rate of cardiovascular events, major limb events, and inpatient admissions.